The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity ...

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights. Q1 ...

Solo Pace announced today that it received FDA clearance for its SoloPace Control System for temporary pacing in TAVR ...

Canaccord analyst William Plovanic raised the firm’s price target on Edwards Lifesciences (EW) to $75 from $71. The firm said Edwards delivered ...

General Hospital (GH) in Ernakulam prepares for first heart transplant surgery in May, following successful cardiac care initiatives.

Edwards Lifesciences Corp (EW) reports an 8% increase in total sales, raises full-year guidance, and achieves significant ...

Edwards Lifesciences reports 8% Q1 2025 sales growth to $1.41B, driven by TAVR & TMTT. Discover regulatory catalysts & future growth insights.

Edwards Lifesciences Corporation ( NYSE: EW) Q1 2025 Earnings Conference Call April 23, 2025 5:00 PM ET Mark Wilterding - SVP, Global Finance Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - ...

Tariff talk will continue in the second week of earnings season, but the updates could also shed light on trends and ...

CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal ...